Optimal timing of initial debridement for necrotizing soft tissue infection: A Practice Management Guideline from the Eastern Association for the Surgery of Trauma

Rondi B. Gelbard, MD, Paula Ferrada, MD, D. Dante Yeh, MD, Brian H. Williams, MD, Michele Loor, MD, James Yon, MD, Caleb Mentzer, DO, Kosar Khwaja, MD, MBA, MSc, Mansoor A. Khan, MBBS, PhD, Anirudh Kohli, MD, Eileen M. Bulger, MD, and Bryce R.H. Robinson, MD, Atlanta, Georgia

AAS T Continuing Medical Education Article

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Surgeons and the American Association for the Surgery of Trauma. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™
The American College of Surgeons designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Of the AMA PRA Category 1 Credit™ listed above, a maximum of 1 credit meets the requirements for self-assessment.

Credits can only be claimed online

Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this journal activity, must ensure that anyone in a position to control the content of J Trauma Acute Care Surg articles selected for CME credit has disclosed all relevant financial relationships with any commercial interest. Disclosure forms are completed by the editorial staff, associate editors, reviewers, and all authors. The ACCME defines a ‘commercial interest’ as ‘any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.’ ‘Relevant’ financial relationships are those (in any amount) that may create a conflict of interest and occur within the 12-months preceding and during the time that the individual is engaged in writing the article. All reported conflicts are thoroughly managed in order to ensure any potential bias within the content is eliminated. However, if you perceive a bias within the article, please report the circumstances on the evaluation form.

Please note we have advised the authors that it is their responsibility to disclose within the article if they are describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

Disclosures of Significant Relationships with Relevant Commercial Companies/Organizations by the Editorial Staff
Ernest E. Moore, Editor: PI, research support and shared U.S. patents Haemonetics; PI, research support, Instrumentation Laboratory, Inc.; Co-founder, Thrombo Therapeutics. Associate Editors David Hoyt, Ronald V. Maier and Steven Shackford have nothing to disclose. Editorial staff and Angela Sassaia have nothing to disclose. Michelle Loor, MD, discloses payment of registration for conference and travel expenses from LifeCell and Intuitive Surgical.

Eileen Bulger, MD, discloses a PI grant from Atox Bio.

Reviewer Disclosures
The reviewers have nothing to disclose.

Cost
For AAST members and Journal of Trauma and Acute Care Surgery subscribers there is no charge to participate in this activity. For those who are not a member or subscriber, the cost for each credit is $25.

AAST Continuing Medical Education Article

Objectives
After reading the featured articles published in the Journal of Trauma and Acute Care Surgery, participants should be able to demonstrate increased understanding of the material specific to the article. Objectives for each article are featured at the beginning of each article and online. Test questions are at the end of the article, with a critique and specific location in the article referencing the question topic.

Claiming Credit
To claim credit, please visit the AAST website at http://www.aast.org/ and click on the “e-Learning/MOC” tab. You must read the article, successfully complete the post-test and evaluation. Your CME certificate will be available immediately upon receiving a passing score of 75% or higher on the post-test. Post-tests receiving a score of below 75% will require a retake of the test to receive credit.

System Requirements
The system requirements are as follows: Adobe® Reader 7.0 or above installed; Internet Explorer® 7 and above; Firefox® 3.0 and above, Chrome® 8.0 and above, or Safari™ 4.0 and above.

Questions
If you have any questions, please contact AAST at 800-789-4006. Paper test and evaluations will not be accepted.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Neocrrotizing soft tissue infections (NSTI) are severe and rapidly progressing infections with extremely high morbidity and mortality rates. The term “neocrrotizing soft tissue infection” encompasses all types of infection involving any layers of the soft tissue including superficial fascia, deep fascia or muscle. The clinical manifestations range from pyoderma to necrotizing cellulitis, myositis, progressive bacterial synergistic gangrene, and life-threatening neocrrotizing fasciitis.

Necrotizing soft tissue infections are commonly seen in the extremities and abdominal walls, although any part of the body can be affected. Fournier gangrene, for example, is a fulminant form of NSTI that involves the perineal, genital, or perianal regions in men. Even though there are several definitions and classification systems that have been used to describe these infections, they all have similar pathophysiologic, clinical characteristics, and share the same diagnostic and treatment strategies. Early diagnosis and treatment are essential, because the mortality ranges from 10% to 17% with some sources citing mortality rates up to 73%.

Necrotizing soft tissue infections can be caused by polymicrobial (Type I) or monomicrobial organisms (Type II). Monomicrobial infections account for 10% of NSTI and are most commonly caused by Group A β-hemolytic streptococci, especially the toxin producing strains of S. pyogenes. Other less common organisms include Vibrio vulnificus (Type III NSTI), which is found in marine environments; Aeromonas hydrophila, found in fresh or brackish water; and Clostridium perfringens. Poly-microbial infections account for the majority of infections and involve a combination of bacteria, including Staphylococcus, Streptococcal species, Escherichia coli, Bacteroides fragilis, or Clostridium species.

There are no specific diagnostic criteria for NSTI as patients can present with a wide range of clinical findings. In fact, NSTI involving the fascial planes is often not recognized during the initial examination due to a paucity of skin findings, or markers of abscess or cellulitis.

Submit: October 4, 2017, Revised: January 18, 2018, Accepted: January 31, 2018
Published online: February 27, 2018

From the Division of Trauma and Surgical Critical Care at Grady Memorial Hospital, Department of Surgery, Emory University School of Medicine (R.B.G.), Atlanta, Georgia; Division of Acute Care Surgery, Department of Surgery, Virginia Commonwealth University (P.F.), Richmond, Virginia; Division of Trauma and Critical Care, Department of Surgery, University of Miami (D.D.Y., C.M.), Miami, Florida; Department of Surgery, UT Southwestern Medical Center (B.H.W.), Dallas, Texas; Division of Critical Care and Acute Care Surgery, Department of Surgery, University of Minnesota (M.L.), Minneapolis, Minnesota; Department of Surgery, Swedish Medical Center (J.Y.), Englewood, Colorado; Department of Surgery and Critical Care Medicine, McGill University Health Centre (K.K.), Montreal, Canada; St. Mary’s Hospital Major Trauma Center, Imperial College Healthcare (M.K.), London, United Kingdom; Division of Acute Care Surgery, Department of Surgery, Thomas Jefferson University Hospital (A.K.), Philadelphia, Pennsylvania; and Division of Trauma, Burn and Critical Care Surgery, Department of Surgery, Harborview Medical Center (E.M.B., B.R.H.R.), University of Washington, Seattle, Washington.

Address for reprints: Rondi B. Gelbard, MD, Emory University School of Medicine, 69 Jesse Hill Jr. Drive, SE, Glenn Memorial Building, Room 315, Atlanta, Georgia 30303; email: rgelbar@emory.edu.

DOI: 10.1097/TA.0000000000001857

© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Repeated debridement may be required, with several groups advising routine surgical reexploration within 24 hours. Broad-spectrum antibiotics that include gram-negative, gram-positive, and anaerobic coverage should also be initiated immediately after the diagnosis is suspected and continued until adequate source control is achieved. Hyperbaric oxygen (HBO) therapy and intravenous immunoglobulin (IVIg) have been used as adjunctive strategies in the management of NSTI. Hyperbaric oxygen therapy delivers oxygen at two to three times atmospheric pressure, leading to high arterial and tissue oxygen tension. Although it is thought to have antibacterial effects, promote wound healing, and inhibit reperfusion injury, the use of HBO for NSTI is somewhat controversial. Pooled IVIg binds certain bacterial exotoxins, limiting the systemic inflammatory response. Intravenous immunoglobulin has been shown to reduce mortality in sepsis and septic shock, but there are currently no data to support its routine use for NSTI.

Although source control is a priority in the management of NSTI, early surgical intervention may be delayed due to prolonged intervals between symptom onset and presentation, particularly for patients requiring transfer to a specialized regional center. Making the correct diagnosis can be challenging, especially among immunocompromised patients that do not manifest typical clinical or laboratory signs of NSTI. Studies have shown that patients with malignancy or those undergoing treatment with steroids or chemotherapy are susceptible to delays in debridement and have a higher in-hospital mortality. Patients that present in shock may be deemed too unstable to undergo immediate surgical intervention and admission to the intensive care unit (ICU) for aggressive resuscitation can lead to delays in surgical debridement.

Even though it has been established that early operative debridement is the mainstay of treatment for these aggressive infections, there is no consensus regarding the optimal timing of initial debridement. The purpose of this systematic review and meta-analysis was to create a practice management guideline for acute care surgeons regarding the optimal timing of initial debridement for NSTI, using a framework established by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group. The creation of this guideline was overseen by the Eastern Association for the Surgery of Trauma Practice Management Guideline Committee.

**OBJECTIVES**

The purpose of this practice management guideline was to define whether the timing of initial operation (early versus late) has an impact on patient outcomes. The population (P), intervention (I), comparator (C), and outcome (O) questions were defined as follows:

**PICO QUESTION:** In adult and pediatric patients with NSTI (P), should early (<12 hours) initial debridement (I) versus late (≥12 hours) initial debridement (C) be performed to decrease mortality (O)?

**MATERIALS AND METHODS**

**Identification of References**

Inclusion criteria consisted of articles published in the English language that included adult and pediatric patients requiring surgical intervention for the management of NSTI. Letters to the editor, single-case reports, book chapters, and review articles were excluded.

Two professional librarians conducted a systematic search from January 1987 until September 2015 using the PubMed, EMBASE, and the Cochrane Library databases of published studies. The searches were done using Medical Subject Headings (MeSH) terms (Necrotizing[All Fields] AND (“fasciitis”[MeSH Terms] OR “fascitis”[All Fields]) AND (“debridement”[MeSH Terms] OR “debridement”[All Fields]) AND (“methods”[Subheading] OR ‘methods’[All Fields] OR “methods”[MeSH Terms]) AND ((“necrosis”[MeSH Terms] OR “necrosis”[All Fields]) AND (“mortality”[Subheading] OR “mortality”[All Fields] OR “mortality”[MeSH Terms]) AND (“time”[MeSH Terms] OR “time”[All Fields]) AND Factors[All Fields]) OR “necrosis”[MeSH Terms] OR “necrosis”[All Fields] AND (“debridement”[MeSH Terms] OR “debridement”[All Fields]) AND timing[All Fields]. In addition to the electronic search, we hand-searched the bibliographies of recent reviews and articles.

The electronic literature search identified 287 articles. Two independent reviewers then screened the titles and abstracts for the PICO inclusion criteria. Any disagreement on inclusion was resolved by consensus of the entire writing group. Two-hundred and forty-five studies were excluded as they were case...
TABLE 1. Summary of Selected Studies

<table>
<thead>
<tr>
<th>Included Studies</th>
<th>Timing of Early Debridement, h</th>
<th>Early/Late Debridement (No. Patients)</th>
<th>Mortality Rate Early Late</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chao et al. (2013)</td>
<td>&lt;12</td>
<td>53/68</td>
<td>8 (15%)</td>
<td>27 (39%)* All patients had Vibrio vulnificus NSTI</td>
</tr>
<tr>
<td>Kobayashi et al. (2011)</td>
<td>≤12</td>
<td>22/25</td>
<td>1 (4.5%)</td>
<td>7 (28%)* High proportion of diphtheroid infection</td>
</tr>
<tr>
<td>Pakula et al. (2012)</td>
<td>≤12</td>
<td>34/20</td>
<td>5 (15%)</td>
<td>3 (18%) Standardized resuscitation protocol</td>
</tr>
<tr>
<td>Pandey et al. (2009)</td>
<td>Not defined</td>
<td>21/49</td>
<td>5 (23.8%)</td>
<td>10 (20.4%) Pediatric patients and historical controls; limited debridement in late group</td>
</tr>
<tr>
<td>Rieger et al. (2007)</td>
<td>&lt;24</td>
<td>6/10</td>
<td>1 (16%)</td>
<td>2 (20%) Small sample size</td>
</tr>
<tr>
<td>Sudarsky et al. (1987)</td>
<td>&lt;12</td>
<td>7/26</td>
<td>0 (0%)</td>
<td>2 (6%)* Lower in-hospital mortality compared to other studies</td>
</tr>
<tr>
<td>Excluded studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boyer et al. (2009)</td>
<td>Not defined</td>
<td>80</td>
<td>42 (40.6%)</td>
<td>Did not define early vs. late debridement</td>
</tr>
<tr>
<td>Okoye et al. (2013)</td>
<td>≤24</td>
<td>46/18</td>
<td>3 (6.5%)</td>
<td>6 (33.3%)* Prospective study focused on re-debridement; non-randomized</td>
</tr>
</tbody>
</table>

*p < 0.05.

Minor heterogeneity existed given differences in the patient populations and variability in the types of surgery performed for NSTI debridement. These differences across studies were examined to assess the clinical and methodological heterogeneity. Review Manager X.6 (RevMan5, Cochrane Community, London, United Kingdom) was used to calculate the Q statistic. The I² statistic (%) was used to determine the proportion of variation between studies attributable to heterogeneity and categorized as low (25%–49%), moderate (50%–74%), or high (74%–100%). Final recommendations also considered the overall quality of the evidence, the balance between desirable and undesirable effects, patient values, and preferences, as well as resource utilization and cost estimates.

RESULTS

Results for the Timing of NSTI Debridement Less Than 12 Hours After Suspected Diagnosis

PICO QUESTION: In adult and pediatric patients with NSTI (P), should early (<12 hours) initial debridement (I) versus late (≥12 hours) initial debridement (C) be performed to decrease mortality (O)?

Qualitative Synthesis

Our search yielded six studies that addressed the critical outcome of mortality following operative debridement for NSTI. These are summarized in Table 1. There were

Figure 2. Forest plot for early (<12 h) vs. late (≥12 h) debridement in NSTI. Outcome = mortality.
no randomized controlled trials included in our analysis. A total of 143 patients were managed with early operative debridement (<12 hours) versus 198 in the late (≥12 hours) debridement group. Across all studies, there was an overall mortality rate of 14% in the early group versus 25.8% in the late group.

The largest of the retrospective studies by Chao et al.\textsuperscript{20} compared the impact of early (<12 hours) debridement in 53 patients with \textit{V. vulnificus} NSTI to late (≥12 hours after admission) debridement in 68 patients, and found a significant difference in mortality rates (15% vs. 39%, \(p = 0.037\)). One advantage of this study is that all patients had NSTI due to \textit{V. vulnificus} thereby avoiding any confounding due to type of organism. It is important to note that in this study, all patients presented with sepsis and over 50% had septic shock on admission. Those who underwent late debridement were more likely to be hypotensive with higher APACHE II scores. It is possible that debridement was delayed in these patients due to their hemodynamic instability.

A retrospective study of 47 patients with NSTI by Kobayashi et al.\textsuperscript{21} found that the mortality among patients undergoing early debridement (≤12 hours from the time of ED admission) was significantly lower than that of patients undergoing late (>12 hours) debridement (4.5% vs. 28%, \(p = 0.033\)). Delayed debridement was also associated with higher incidence of septic shock and acute kidney injury, as well as an increased number of debridements. This study was limited by the small number of patients. It is also worth noting that they had a high proportion of infections caused by diphtheroids which tend to cause more severe skin and soft tissue damage and therefore may be recognized earlier than NSTI caused by less aggressive organisms.

A retrospective analysis of 54 patients with NSTI by Pakula et al.\textsuperscript{22} found that a delay to surgery (>12 hours from admission) did not impact mortality (15% for early vs. 18% for delayed, \(p = 1.0\)). Limitations of this study include its small sample size and heterogeneous patient population, as well as the fact that patients were not randomized to treatment groups. In fact, the majority of patients were managed with early debridement. However, all patients were resuscitated according to a standardized protocol, eliminating potential confounders due to variations in sepsis management.

Pandey et al.\textsuperscript{23} conducted a retrospective study of 70 pediatric patients with NSTI. Patients underwent conservative debridement (limited to necrotic skin) 3 days to 5 days after starting antibiotics. These were compared to a group of historic controls (two years prior to the conservative group) that underwent early aggressive surgical debridement. The actual timing of the early debridement was never defined in this study, but it was reported to have occurred immediately after the diagnosis of NSTI was made. The mortality was not significantly different between the two groups (20.4% vs. 23.8% in the conservative and early groups, respectively; \(p > 0.05\)). The higher overall mortality reported in this study may have been because several of the patients were premature neonates. Many of the patients included in this study were also of lower socioeconomic status and suffered from malnutrition. Limitations of this study include the fact that exact timing of early aggressive debridement is not defined, it uses historical controls and the surgical therapy is described as “conservative debridement” which is generally not considered standard of care.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Risk of Bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other Considerations</th>
<th>No. Patients</th>
<th>Effect</th>
<th>Absolute (95% CI)</th>
<th>Relative (95% CI)</th>
<th>CI, confidence interval</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Debridement (≤12 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 Observational Studies*</td>
<td>Not serious</td>
<td>Net serious</td>
<td>Serious*</td>
<td>None</td>
<td>Very Low</td>
</tr>
<tr>
<td>Late Debridement (&gt;12 h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 Observational Studies with limited outcomes.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*All observational or retrospective studies with limited outcomes.
A small retrospective study of 16 patients with NSTI by Rieger et al. found a mortality rate of 16% in the six patients undergoing early (<24 hours) debridement versus 20% in the 10 patients undergoing late (224 hours) debridement, although this did not reach statistical significance given the small sample size. In a retrospective study of 33 patients with NSTI by Sudarsky et al., patients who were debrided within 12 hours of admission had a lower mortality than those in whom debridement was delayed for 12 hours to 48 hours (0% vs. 6.1%, respectively). A third group of patients debrided after 48 hours also had a lower mortality rate, perhaps suggesting that they had a less aggressive form of the disease.

Quantitative Synthesis (Meta-analysis)

A comparison of early versus late debridement with mortality as an outcome was found in six of the studies. Analysis of the pooled data showed that early debridement was associated with lower mortality than late debridement (Fig. 2). There was a mild amount of heterogeneity ($I^2 = 21\%$).

Grading the Evidence

The majority of data was retrospective in nature, and there were no randomized controlled trials included in this analysis. Applying the GRADE framework to the outcome of reduced mortality rates, the overall quality of evidence was very low due to retrospective nature of the studies being considered and the small number of studies fulfilling criteria. The evidence was downgraded for risk of bias and imprecision, and inconsistency in the definition of “early” debridement for NSTI (Table 2).

Recommendation

**PICO QUESTION:** In adult and pediatric patients with NSTI (P), should early (<12 hours) initial debridement (I) versus late (≥12 hours) initial debridement (C) be performed to decrease mortality (O)?

We recommend that patients undergo early initial debridement for NSTI within 12 hours of diagnosis (very low quality of evidence, very large magnitude of effect) (Fig. 3).

Our recommendation considers the quality of evidence, balance between desirable and undesirable effects, patient values and preferences, as well as resource utilization and cost estimates. Despite the overall quality of evidence being very low, NSTI is a condition with a high moribidity and mortality. Patients often require prolonged hospital and ICU lengths of stay, making resource utilization and health care–related costs for NSTI quite high. We considered that most patients and hospitals would place a high value on avoidance of mortality and infectious complications related to delayed management of NSTI. These factors resulted in the formulation of a strong recommendation by the group. The desirable effects of adherence to our recommendation likely outweigh the undesirable effects.

**FUTURE INVESTIGATIONS**

Despite significant advances in management as well as improved knowledge regarding NSTIs, establishing an early diagnosis remains challenging. Future research should be aimed at investigating the accuracy of imaging, developing predictive models and validating risk calculators to assist with the diagnosis of NSTI. Given that patients with NSTI often require multiple trips to the operating room for debridement and reconstruction, there is also a need to better define the optimal timing for redebridement.

There is currently no conclusive data on the use of adjunctive treatments such as HBO. Given the lack of proven benefit from HBO and its potential to limit or delay delivery of care, future studies should define which patients might benefit from this therapeutic modality. In addition, there is some data to suggest that when used in conjunction with surgical intervention and appropriate antimicrobial therapy, IVIg and biomodulators may provide a clinically significant treatment benefit. However, the data is inconsistent and more evidence is needed before such interventions are used on a routine basis.

**USING THESE GUIDELINES IN CLINICAL PRACTICE**

This guideline represents an overview of the literature regarding the timing of initial debridement for NSTI. The literature we reviewed supports early (<12 hours) initial debridement for NSTI in adult and pediatric patients to decrease mortality. There are currently no formal protocols for diagnosis and initial management of NSTI; however, there is evidence to suggest that protocolized management may lead to improved outcomes. In-hospital protocols to guide rapid assessment of patients’ clinical status, early resuscitation, initiation of broad-spectrum antibiotics and to determine the need for transfer to a specialized regional center may help avoid delays in definitive care. Most patients with NSTI are initially seen at nonreferral centers that may not be equipped to provide the necessary level of care. This complex surgical problem should be treated at specialized regional centers with experts who are proficient in the diagnosis and management of NSTI; however, there is evidence to suggest that protocolized management may lead to improved outcomes. If transfer to a larger tertiary care center is deemed necessary, transport systems should be in place to transfer the patient quickly and efficiently to avoid significant delays in surgical debridement. The long-term management of NSTI requires a complex multidisciplinary approach that extends well beyond the operative and resuscitation period. Specialized centers should have readily available surgical and ICU teams, wound care specialists, nutritionists, and physical and occupational therapists, because coordination of care among all services is essential for achieving the best long-term outcomes in NSTI.

**Figure 3.** Summary of recommendations.

© 2018 Wolters Kluwer Health, Inc. All rights reserved.
AUTHORSHIP
P.F. served as EAST Guideline Section liaison. R.B.G., P.F., D.D.Y., M.L. formulated the PICO questions, conducted the literature search and screened titles and abstracts. R.B.G., P.F., D.D.Y., B.W. and M.L. performed the full text review. R.B.G., P.F., D.D.Y., B.W., M.L., J.Y., C.M., K.K., M.K., and A.K. abstracted data from selected articles. All authors appraised the evidence and contributed to the final recommendations. B.W. and P.F. contributed the GRADE table and forest plot. R.B.G. drafted the initial manuscript, which all authors critically revised.

ACKNOWLEDGMENT
We gratefully acknowledge Bryce H. Robinson, MD and Eileen Bulger, MD, from the University of Washington, Seattle, WA for their expertise and guidance.

DISCLOSURE
The author declares no conflicts of interest. Source of Funding: None

REFERENCES